AbbVie gives Viekira-dependent 2015 guidance as Anthem chooses Harvoni
This article was originally published in Scrip
Executive Summary
AbbVie announced 2015 financial guidance after the stock market closed on 8 January, but the company's share price did not rise despite an expected 30% increase in earnings for the year, likely because of a second reimbursement victory for its hepatitis C rival Gilead Sciences.